Albert David Ltd

Albert David, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend with a 25.31% decline over the past six trading days. Its one-year performance shows a 34.47% drop, contrasting with the Sensex's gain of 6.03%.

Albert David, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low of Rs. 970 amid significant volatility. The stock has declined 19.26% over the past five days and is trading below all major moving averages, reflecting ongoing challenges in its market performance.

Albert David, a microcap company in the Pharmaceuticals & Drugs sector, announced its financial results for the quarter ending December 2024 on February 12, 2025. The results indicate a significant shift in the company's financial performance, prompting stakeholders to closely examine the implications for future strategies and operations.

Albert David, a microcap pharmaceutical company, has experienced a recent evaluation adjustment following a decline in profit before tax in Q2 FY24-25. The company's reliance on non-operating income raises concerns about its core operational performance, while modest net sales growth suggests a need for strategic initiatives to enhance competitiveness.

Albert David, a microcap pharmaceutical company, has reported a flat performance for the quarter ending September 2024, with a slight improvement in its score. The company's operating cash flow and net sales have shown positive trends, but there are concerns about a significant decrease in profit and a decreasing dividend payout ratio. Investors are advised to hold their stock and monitor future financial reports closely.

Albert David Ltd., a microcap pharmaceutical company, has reached a 52-week and all-time high stock price of Rs. 1752.95 on September 3rd, 2024. With a 'Hold' recommendation from MarketsMOJO and outperforming its sector, the company has shown strong potential and growth in the past year, making it a promising investment in the pharmaceutical industry.

Albert David Ltd., a microcap pharmaceutical company, has reached an all-time high in its stock price on September 3rd, 2024. Despite being only 0.94% away from its 52-week high, the company's stock has outperformed the sector by 1.05% and has been on a consecutive gain streak for the past 4 days. With strong performance and growth potential, Albert David is a promising player in the industry.

Microcap pharmaceutical company Albert David . has achieved a new milestone in its stock price, hitting a 52-week high of Rs.1732 on September 2nd, 2024. The stock has been performing well, outperforming the sector by 3.21% and showing a consecutive rise in the past three days. With a 'Hold' rating from MarketsMOJO and trading higher than its moving averages, the company's strong performance and potential for growth have caught the attention of investors and market analysts.

Albert David Ltd., a microcap pharmaceutical company, has reached an all-time high in its stock price on September 2nd, 2024. The stock has been gaining for the past three days, with a 9.27% increase in returns. It has also outperformed the sector by 2.44% today. According to MarketsMOJO, the stock's current call is 'Hold' and it has shown a remarkable performance in the past year with a 114.93% increase in its stock price. This showcases the company's strong growth and potential in the pharmaceutical industry.

Albert David Ltd., a microcap pharmaceutical company, has been making headlines in the stock market with its stock price reaching an all-time high of Rs.1732 on September 2nd, 2024. The company has been outperforming the sector by 2.44% and has seen a 9.27% increase in the past three days. With a positive trend and impressive performance, Albert David Ltd. is a company to watch out for in the pharma industry.

Albert David Ltd., a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching a 52-week high of Rs. 1647 on August 29, 2024. According to MarketsMOJO, the stock call for Albert David is 'Hold', indicating strong performance but not the best time to buy or sell. The company's stock has consistently outperformed the sector and its moving averages, showcasing its positive trend and growth potential. However, this article does not offer any recommendations or predictions and advises investors to do their own research before making any investment decisions.

Albert David Ltd., a microcap pharmaceutical company, has reached an all-time high in its stock price on August 29, 2024. The company's stock call has been labeled as 'Hold' by MarketsMOJO. Albert David's stock is currently trading close to its 52-week high and has outperformed its sector by 1.14%. It has also shown a significant increase in the past year compared to the Sensex performance, showcasing its strong performance in the pharmaceutical industry.

Albert David, a microcap pharmaceutical company, received a 'Hold' rating from MarketsMOJO despite a flat financial performance in the quarter ending June 2024. The company has shown strong operating cash flow and a healthy amount of cash and cash equivalents, but there are concerns about falling profit and dividend payout ratio, low operating profit, and high income from non-business activities.

Albert David ., a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio. Despite strong financial performance in recent quarters, concerns about long-term growth and lack of interest from domestic mutual funds may have influenced the decision.

Albert David ., a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its strong financial performance and positive outlook. The company has a low Debt to Equity ratio, consistent positive results, and a strong cash position. Technical indicators also suggest a bullish trend. However, there are risks such as poor long-term growth and low stake from domestic mutual funds.

Albert David ., a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio. Despite positive results and a strong cash position, its slow long term growth and lack of interest from domestic mutual funds may be a concern for investors.

Albert David ., a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its strong financial performance and positive outlook. The company's low Debt to Equity ratio, consistent positive results, and high cash reserves make it an attractive investment option. However, slow long-term growth and low stake from domestic mutual funds should also be considered.

Albert David, a microcap pharmaceutical company, has reported a positive financial performance in the quarter ending March 2024. The company's stock has been given a 'Hold' call by MarketsMOJO, with a score of 9 out of 10. The major highlight is the significant growth in Profit After Tax, but concerns have been raised about the company's Non Operating Income.

Albert David ., a microcap pharmaceutical company, was downgraded to a 'Hold' by MarketsMOJO on March 5th, 2024. This was due to its low Debt to Equity ratio and positive financial results for the last three quarters. The stock is currently in a Mildly Bullish range and has an attractive valuation, but its long-term growth potential and lack of interest from domestic mutual funds may be a concern for investors.